Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2-dimethylbenzofuran-3-carboxamide

A pharmaceutical composition comprising a crystalline form of the compound of Formula A

• wherein the crystalline form of the compound of Formula A has an x-ray powder diffraction pattern when measured using a CuKα radiation comprising peaks expressed in degrees 2-theta (2θ) at 5.3±0.2, 10.7±0.2, 13.9±0.2, and 14.6±0.2;
• a pharmaceutically acceptable carrier;
• and
• one or more other therapeutically active compounds;
• wherein the content of other crystalline forms of the compound of Formula A in said pharmaceutical composition is less than 40% by weight.